M&Ms And PBMs: Sandoz CEO Talks Antibiotics And Ustekinumab

Richard Saynor Discusses ‘Offensive’ US Antibiotics Pricing And Reveals Tie-Up For Stelara Rival

 
• By Dave Wallace

At the J.P. Morgan Healthcare Conference in San Francisco, Sandoz CEO Richard Saynor commented on the “offensively” low pricing for antibiotics in the US – “less than a packet of M&Ms” – while also revealing that the firm has struck a deal with a US PBM for its Samsung Bioepis-partnered Pyzchiva ustekinumab biosimilar to Stelara.

Antibiotics cost “less than a packet of M&Ms” in the US, Saynor highlighted (Shutterstock)

In a comprehensive presentation at the J.P. Morgan Healthcare Conference in San Francisco, Sandoz CEO Richard Saynor talked through many of Sandoz’s key strategic priorities, including its burgeoning biosimilars business, its consistent sales growth, and opportunities on the horizon in terms of upcoming losses of exclusivity – along with new product categories like GLP-1s and antibody drug conjugates (ADCs).

While many of these aspects were covered in similar detail in Generics Bulletin’s recent exclusive three-part interview with Saynor, the Sandoz CEO also used the J.P

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Generics Bulletin